Evidence map›Paper›PMID 42199292›Full record

ArticleLiver cancer2026

An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis.

Markus Peck-Radosavljevic, Akhmed Abdelgafur, Alessandro Granito, Antonio Gasbarrini, Yuk Ting Ma, Edward Mena, José Luis Lledó-Navarro, José Presa, Arndt Weinmann, Miriam T Levy and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Markus Peck-RadosavljevicDepartments of Internal Medicine and Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Akhmed AbdelgafurDepartments of Oncology, Nizhny Novgorod Regional Clinical Oncological Dispensary, Nizhny Novgorod, Russia.
Alessandro GranitoDepartment of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy.
Antonio GasbarriniDepartment of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Yuk Ting MaThe Cancer Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
Edward MenaPasadena Liver Center, California Liver Research Institute, Pasadena, CA, USA.
José Luis Lledó-NavarroGastroenterology and Hepatology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
José PresaUnidade Local de Saúde de Trás os Montes e Alto Douro, Hospital de Vila Real, Vila Real, Portugal.
Arndt WeinmannDepartment of Internal Medicine I, University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
Miriam T LevyDepartment of Gastroenterology and Liver, Liverpool Hospital, Sydney, NSW, Australia.
Adriano PellicelliLiver and Transplant Unit, San Camillo Forlanini Hospital, Rome, Italy.
Dirk-Thomas WaldschmidtDepartment of Gastroenterology and Hepatology, University of Cologne, Cologne, Germany.
Henrik Toft SørensenDepartment of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
Lipika GoyalDepartment of Medicine, Division of Oncology, Stanford Cancer Center, Palo Alto, CA, USA.
Min RenBiostatistics, Eisai Inc., Nutley, NJ, USA.
Hakim SaalMedical Affairs, Eisai Inc., Nutley, NJ, USA.
Chinyere E OkparaClinical Development, Eisai Ltd., Hatfield, UK.
Tim MeyerDepartment of Oncology, Royal Free London NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The phase 3 REFLECT trial demonstrated the efficacy and safety of lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). We report results from STELLAR, a non-interventional post-marketing study. The primary objectives were to characterize hepatotoxicity and overall safety of lenvatinib in patients from Western regions with uHCC. Methods: STELLAR was a prospective, open-label, observational, phase 4 study of patients treated with lenvatinib ( Results: The median duration of treatment with lenvatinib or sorafenib was 6.5 months (range, 0.2-33.1 months) and 4.4 months (range, 0.5-30.7 months), respectively. Hepatotoxicity treatment-emergent adverse events (TEAEs) were observed in 26.9% of lenvatinib-treated patients and 33.3% of sorafenib-treated patients. The most frequently reported hepatotoxicity TEAEs were hepatic encephalopathy (7.8%; lenvatinib cohort) and ascites (11.4%; sorafenib cohort), respectively. Overall, 85.0% of lenvatinib-treated patients and 84.6% of sorafenib-treated patients experienced ≥1 TEAE. Median overall survival (95% CI) was 16.9 months (14.1-not estimable) in lenvatinib-treated patients. Conclusion: Our findings support the established safety and efficacy of lenvatinib in first-line patients with uHCC.

Indexed as

Hepatocellular carcinomaLenvatinibPhase 4Sorafenib

Identifiers

PMID42199292
PMCPMC13200844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.